Given that both HRD and TP53 mutations are associated with race in both ER-negative and ER-positive breast cancer (26, 27), and strong immunogenicity in breast tumors from Black patients (31), novel predictive markers are an unmet clinical need. This evidence concerns the gene TP53 and breast neoplasm.